Results 61 to 70 of about 30,070 (260)

Optical Genome Mapping Reveals Frequent Cryptic Structural Aberrations in Normal Karyotype Acute Myeloid Leukemia

International Journal of Cancer, EarlyView.
Acute myeloid leukemia adult cases often appear cytogenetically normal when analyzed with conventional karyotyping. However, acquired structural variants may escape routine detection. Here, optical genome mapping detected diverse genomic alterations in nearly half of the analyzed cytogenetically normal cases.
Tuuni Turtinen, Andriana Valkama, Christopher Wray, Sandra Vorimo, Hannele Räsänen, Eeva‐Riitta Savolainen, Katri Pylkäs, Tuomo Mantere   +7 more
wiley   +1 more source

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, EarlyView.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source

Case Report: Free-Floating Intracoronary Thrombus: Who Is the Convict?

Frontiers in Oncology, 2022
In young patients, especially with no traditional coronary risk factors, hypercoagulable states may always be considered as an alternative cause of acute coronary syndromes.
Francesca Mantovani, Ambra Paolini, Andrea Barbieri, Giuseppe Boriani   +3 more
doaj   +1 more source

Unveiling the roles of extracellular vesicles in hematologic malignancies: Pathogenesis, diagnostic tools, and clinical translation

Interdisciplinary Medicine, EarlyView.
Extracellular vesicles play pivotal roles in both healthy hematopoiesis and hematologic malignancies. They not only regulate hematopoietic stem cell fitness but also drive cancer progression and drug resistance. Their clinical potential spans from serving as non‐invasive biomarkers to acting as innovative therapeutic platforms and drug delivery ...
Fengyu Chen, Zhiyuan Wu, Feng Zhang, Yuan Meng, Hongyan Liao, Tony Y. Hu   +5 more
wiley   +1 more source

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome

Clinical Medicine Insights: Case Reports, 2018
Hydroxyurea (HU) is a drug frequently used in the treatment of chronic myeloproliferative neoplasms. The most common side effects of this drug are pancytopenia, digestive and skin disorders.
Oriol Plans Galván, Hipólito Pérez Moltó, Ariadna Fabià-Mayans, Blanca Xicoy, José Luis Mate, Pilar Ricart Martí   +5 more
doaj   +1 more source

Histiocytosis development and clinical variation through the lens of genomics

The Journal of Pathology, EarlyView.
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps, Astrid GS van Halteren, Tom van Wezel, Pancras CW Hogendoorn   +3 more
wiley   +1 more source

Single-cell analysis based dissection of clonality in myelofibrosis

Nature Communications, 2020
Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
Elena Mylonas, Kenichi Yoshida, Mareike Frick, Kaja Hoyer, Friederike Christen, Jaspal Kaeda, Matthias Obenaus, Daniel Noerenberg, Cornelius Hennch, Willy Chan, Yotaro Ochi, Yuichi Shiraishi, Yusuke Shiozawa, Thorsten Zenz, Christopher C. Oakes, Birgit Sawitzki, Michaela Schwarz, Lars Bullinger, Philipp le Coutre, Matthew J. J. Rose-Zerilli, Seishi Ogawa, Frederik Damm   +21 more
doaj   +1 more source

Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report

, 2012
Introduction An unprovoked thombotic event in a patient is cause for further evaluation of an underlying hypercoaguable state. The investigation should include a thorough search, including checking for a variety of known inherited and acquired ...
Hamilton James, Alison R Moliterno, Naveen Pemmaraju, Andrew M Cameron, James Peter Hamilton, Cameron Andrew M, Moliterno Alison R, Sisson Stephen, Stephen Sisson, Pemmaraju Naveen   +9 more
core   +1 more source

Supplementary Material for: Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24)

, 2023
The translocation t(8;9) produces the fusion gene PCM1-JAK2, resulting in the continuous activation of the JAK2 tyrosine kinase. Myelodysplastic/myeloproliferative neoplasms are the most common disease with t(8;9)/PCM1-JAK2.
Liu S. (3777670), Huo L. (16810644), Yang R. (4136818), Yang X. (3341028), Wu D. (7328072), Chen S. (3601424), Cai P. (16810641), Duan L. (9103853)   +7 more
core   +1 more source

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source